Tesaglitazar
File:Tesaglitazar.png | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C20H24O7S |
Molar mass | 408.46 |
3D model (JSmol) | |
|
Tesaglitazar is a proposed treatment for type 2 diabetes.[1]
- SGLT2 inhibitors have been reported to lower all-cause mortality, reduced hospitalisation for heart failure, lowering weight.[2]
The drug had completed several phase III clinical trials,[3] however in May, 2006 AstraZeneca announced that it had discontinued further development.[4]
References
- ↑ Wilding JP, Gause-Nilsson I, Persson A (2007). "Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes". Diab Vasc Dis Res. 4 (3): 194–203. doi:10.3132/dvdr.2007.040. PMID 17907109.
- ↑ Palmer, Suetonia C; Tendal, Britta; Mustafa, Reem A; Vandvik, Per Olav; Li, Sheyu; Hao, Qiukui; Tunnicliffe, David; Ruospo, Marinella; Natale, Patrizia; Saglimbene, Valeria; Nicolucci, Antonio; Johnson, David W; Tonelli, Marcello; Rossi, Maria Chiara; Badve, Sunil V; Cho, Yeoungjee; Nadeau-Fredette, Annie-Claire; Burke, Michael; Faruque, Labib I; Lloyd, Anita; Ahmad, Nasreen; Liu, Yuanchen; Tiv, Sophanny; Millard, Tanya; Gagliardi, Lucia; Kolanu, Nithin; Barmanray, Rahul D; McMorrow, Rita; Raygoza Cortez, Ana Karina; White, Heath; Chen, Xiangyang; Zhou, Xu; Liu, Jiali; Rodríguez, Andrea Flores; González-Colmenero, Alejandro Díaz; Wang, Yang; Li, Ling; Sutanto, Surya; Solis, Ricardo Cesar; Díaz González-Colmenero, Fernando; Rodriguez-Gutierrez, René; Walsh, Michael; Guyatt, Gordon; Strippoli, Giovanni F M (2021). "Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials". BMJ: m4573. doi:10.1136/bmj.m4573. ISSN 1756-1833.
- ↑ "GALIDA™ (tesaglitazar) Clinical Trial Report Summaries". AstraZeneca. Retrieved 2008-03-17.
- ↑ "AstraZeneca Discontinues Development of GALIDA (tesaglitazar)". AstraZeneca. 2006-05-04. Retrieved 2008-03-17.
Categories:
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Sulfones